Vitamin C pharmacokinetics: implications for oral and intravenous use (2004)

Peer-Reviewed Study · Sebastian J. Padayatty, Hugh Sun, Yaohui Wang, Heike D. Riordan, Mark Levine et al. (National Institute of Diabetes and Digestive and Kidney Diseases, NIH) · April 6, 2004

Sebastian J. Padayatty et al., 2004-04-06: NIH pharmacokinetic study in 17 healthy volunteers plus modelling, showing that oral vitamin C concentrations are tightly controlled while a 50 g intravenous dose predicts plasma concentrations some 60-fold higher (13,400 vs 220 micromol/L).

only intravenous administration of vitamin c produces high plasma and urine concentrations that might have antitumor activity

Conclusions, unpaginated web record

Sebastian J. Padayatty et al., 2004-04-06: NIH pharmacokinetic study in 17 healthy volunteers plus modelling, showing that oral vitamin C concentrations are tightly controlled while a 50 g intravenous dose predicts plasma concentrations some 60-fold higher (13,400 vs 220 micromol/L). Funder: NIH intramural research (NIDDK). Maker: pharmaceutical-grade ascorbic acid, no commercial sponsor. Comparator: dose-ranging within subjects, oral versus intravenous. Conflicts: none declared. This paper supports the book's factual point that IV vitamin C reaches far higher blood levels than oral, and simultaneously explains why the oral-only Mayo trials could not have tested the high-dose hypothesis – it does not show clinical benefit, and the authors call for re-evaluation, not endorsement. The abstract itself lowercases 'vitamin c'; quoted as published.